TScan converts $15M loan principal into 3.13M shares at $4.785

TScan Therapeutics, Inc.

K2 HealthVentures converted $15M of convertible term loan into 3,134,796 voting common shares at $4.785/share.
Shares issued November 20, 2024 under Section 3(a)(9) exemption; no registration statement required.
Conversion reduces debt but dilutes existing stockholders by approximately 5.5% based on shares outstanding.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.